Literature DB >> 15244399

Rituximab-induced acute pulmonary fibrosis.

Rafael J Leon, Americo Gonsalvo, Rafael Salas, Nelly C Hidalgo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15244399     DOI： 10.1016/S0025-6196(11)62171-X

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  13 in total

Review 1.  Pulmonary toxicities from targeted therapies: a review.

Authors:  Nicholas A Barber; Apar Kishor Ganti
Journal:  Target Oncol       Date:  2011-11-11       Impact factor: 4.493

2.  Fatal pulmonary fibrosis after rituximab administration.

Authors:  Marie-Camille Chaumais; Arnaud Garnier; François Chalard; Michel Peuchmaur; Stephane Dauger; Evelyne Jacqz-Agrain; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2009-04-25       Impact factor: 3.714

3.  Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

Authors:  Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

Review 4.  Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

Authors:  Sunad Rangarajan; Morgan L Locy; Tracy R Luckhardt; Victor J Thannickal
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 5.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

6.  Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.

Authors:  Ryoji Kobayashi; Tetsuo Mitsui; Naoto Fujita; Tomoo Osumi; Tomohiro Aoki; Kazunari Aoki; Ritsuro Suzuki; Takahiro Fukuda; Toshihiro Miyamoto; Koji Kato; Hirohisa Nakamae; Hiroaki Goto; Tetsuya Eto; Masami Inoue; Takehiko Mori; Kiminori Terui; Masahito Onizuka; Katsuyoshi Koh; Yuhki Koga; Tatsuo Ichinohe; Akihisa Sawada; Yoshiko Atsuta; Junji Suzumiya
Journal:  Int J Hematol       Date:  2016-10-27       Impact factor: 2.490

7.  Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.

Authors:  Kyu-Hyoung Lim; Ho-Il Yoon; Young Ae Kang; Keun-Wook Lee; Jee Hyun Kim; Soo-Mee Bang; Jae Ho Lee; Choon-Taek Lee; Jong Seok Lee
Journal:  Korean J Intern Med       Date:  2010-02-26       Impact factor: 3.165

8.  A case of organizing pneumonia associated with rituximab.

Authors:  Chi Hoon Maeng; Sang Ouk Chin; Byung Hyuk Yang; Si-young Kim; Hwi-Joong Youn; Kyung Sam Cho; Sun Kyung Baek; Sun Lee
Journal:  Cancer Res Treat       Date:  2007-06-30       Impact factor: 4.679

Review 9.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

10.  Rituximab-induced bronchiolitis obliterans organizing pneumonia.

Authors:  Ahmet B Ergin; Nancy Fong; Hamed A Daw
Journal:  Case Rep Med       Date:  2012-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.